All In Biotech

Drug Trial Radar · NCT01668043

Study to Evaluate Safety and Efficacy of UB-421 Antibody in HIV-1 Infected Adults

A Phase IIa, Open-label, Multiple-Dose Trial to Investigate the Safety and Efficacy of the UB-421 in Asymptomatic HIV-1 Infected Adults

Last checked: Nov 19, 2026Latest source record: Aug 20, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

29

Actual

Start

Sep 2012

Primary completion

Mar 2014

Study completion Mar 2014

Sponsor

Lead sponsor
United BiomedicalIndustry
Sponsor type
Industry
Collaborators
Taipei Veterans General Hospital, Taiwan; Kaohsiung Veterans General Hospital.; UBI Asia in Taiwan
First posted
Aug 17, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this Phase IIa study is to determine whether the antibody (UB-421), targeting the HIV-1 receptor on the CD4 molecule of T-lymphocytes and monocytes, is safe and effective when multiple doses are administered by intravenous infusion to asymptomatic HIV-1 infected adults and to assess pharmacokinetic parameters of the antibody in blood and on cells. The neutralizing activity of UB-421 blocks HIV-1 from binding to its receptor on CD4-positive cells; thus, UB-421 functions as an immunotherapeutic intervention to prevent HIV-1 infection.

Conditions

  • HIV-1 Infection in Adults

Interventions

  • Antibody UB-421Drug

    UB-421 is administered by intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate safety and tolerability of multiple intravenous infusions of two dose cohorts of UB-421Time frame: 16-week study period
  2. To evaluate efficacy by measurement of individual maximal viral load reduction and mean maximal viral load reduction of two dose cohorts of UB-421.Time frame: 16-week study period

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Taipei Veterans General Hospital (TVGH)

    Taipei, Beitou District, Taiwan

  • Kaohsiung Veterans General Hospital (KVGH)

    Kaohsiung City, Zuoying District, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.